Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 580

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 580
---
-K.

Item
9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Not
applicable.

PART
III

Item
10. Directors, Executive Officers and Corporate Governance 

The
following table provides information regarding our current executive officers and directors:

    Name
    Age
    Position

    Executive
    Officers

    Francis
    Knuettel II
    58
    Chief
    Executive Officer and President, Chief Financial Officer, Treasurer and Secretary

    Eric
    Lang
    63
    Chief
    Medical Officer

    Directors

    Todd
    Davis
    64
    Director
    (Chairman of the Board)

    Ezra
    Friedberg
    55
    Director

    Richard
    Malamut
    65
    Director

    Chia-Lin
    Simmons
    51
    Director

    Francis
    Knuettel II 
    58
    Director

Biographic
Information 

Francis
Knuettel II has served as our Chief Executive Officer since July 2023, as our Chief Financial Officer, Treasurer and Secretary
since June 2022, as our Chief Executive Officer since March 2024, and has served as a member of our board of directors since August
2024. Prior to that, from December 2020 to April 2022, he served as Chief Executive Officer and director of Unrivaled Brands,
a California-based operator of cannabis assets in California and Oregon, where he helped grow revenue from an annualized rate
of $10 million to $100 million in six quarters by acquiring three companies in the sector. He also served as Chief Financial Officer
of ONE Cannabis Group from June 2019 to January 2021 and held various roles at MJardin Group, including Chief Strategy Officer,
from August 2018 to January 2019. Prior to MJardin Group, Mr. Knuettel served as Chief Financial Officer of Aqua Metals in 2018
and held the same position at Marathon Patent Group from 2014 to 2018. During Mr. Knuettel’s career, he has helped raise
more than $300 million via venture equity and debt, public equity and debt offerings in the United States and Canada, convertible
debt, PIPEs, bridge loans and other instruments. In addition, he has managed more than 15 mergers and acquisition transactions
of companies as both buyer and seller and has handled large-scale licensing transactions with fortune